

Rabbit anti-Human DR4 Polyclonal Antibody | anti-TNFRSF10A antibody

DR4 Antibody


CATALOG # AAA10950	HOST Rabbit	REACTIVITY Human	APPLICATIONS ELISA, Western Blot
------------------------------	-----------------------	----------------------------	--

PRODUCT SYNONYMS

DR4; Polyclonal Antibody; DR4 Antibody; APO2; CD261; TRAILR1; TRAILR-1; Tumor necrosis factor receptor superfamily member 10A; Death receptor 4; TRAIL receptor 1; tumor necrosis factor receptor superfamily; member 10a; anti-TNFRSF10A antibody


PRODUCT SPECIFICATIONS

Host	Rabbit
Reactivity	Human
Clonality	Polyclonal
Isotype	IgG
Specificity	DR4 antibody has no cross reaction to DR5.
Purity/Purification	DR4 Antibody is affinity chromatography purified via peptide column.
Form/Format	Liquid
Sequence Length	468
Applicable Applications for anti-TNFRSF10A antibody	ELISA, WB (Western Blot)
Application Notes	DR4 antibody can be used for detection of DR4 by Western blot 0.5 mug/mL. A 57 kDa band can be detected. Knockdown (Knockout, KO validated) Antibody
Conjugate	Unconjugated
Immunogen	DR4 antibody was raised against a 20 amino acid peptide near the amino terminus of human DR4.
Buffer	DR4 Antibody is supplied in PBS containing 0.02% sodium azide.
Preparation and Storage	DR4 antibody can be stored at 4 degree C for three months and -20 degree C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.




WB (Western Blot)

Figure 9 KD Validation in HeLa Cells (Horinaka et al., 2005)HeLa cells were transfected with DR4siRNA or LacZ control siRNA. At 24 h after transfection, the cells were treated with or without 20 μM luteolin for 24 h. Western blot analysis was carried out with anti-DR4 antibodies. DR4 expression was markedly reduced after DR4 knockdown.




IHC (Immunohistochemistry)

Figure 7 Immunocytochemistry Validation of DR4 in Human Melanoma Cells (Ekmekcioglu et al., 2008)MeWo melanoma cells were exposed to affinity-purified MDA7/IL-24. After 48 h of treatment, cells were collected and cytopins prepared for cytochemical assessment of their TRAIL receptor (R1 and R2) expression (anti-DR4 or anti-DR5, AEC, hematoxylin). Both DR4 and DR5 expression were upregulated in MeWo cells after treatment.




WB (Western Blot)

Figure 5 KD Validation in SW480 Cells (Goda et al., 2008)The expression of DR4 was knocked down via DR4 siRNA, 24 h later cells were treated with dipyridamole for 24 h. DR4 protein expression detected by anti-DR4 antibodies was disrupted. Dipyridamole up-regulated the expression of DR4.




IHC (Immunohistochemistry)

Figure 8 Immunohistochemistry Validation of DR4 in Human Colon Tumors (Devetzi et al., 2016)DR4 expression in human colon tumors detected by anti-DR4 antibodies. Strong immunoreactivity is shown for DR4 in T167. Moderate immunoreactivity is shown for DR4 in T187.



IF (Immunofluorescence)

Figure 6 Immunofluorescence Validation of DR4 in Rat Brain (Cantarella et al., 2014)DR4 protein expression detected by anti-DR4 antibodies was increased after transient brain ischemia (tMCAO) and decreased after pre-conditioning stimulus. Confocal microscopic images displaying NeuN (a,d, g) (green), DR4 (b, e, h) (red), and Merge (c, f, i) (yellow) in the brain peri-ischemic region of rats after 5 h.



ICC (Immunocytochemistry)

Figure 4 Immunocytochemistry Validation of DR4 in HeLa CellsImmunocytochemical analysis of 4% paraformaldehyde-fixed HeLa cells labeling DR4 with 1167 at 2 μg/ml, followed by goat anti-rabbit IgG secondary antibody at 1/250 dilution (red). Image showing membrane staining on HeLa cells.

ADDITIONAL INFORMATION

Related Product Information for anti-TNFRSF10A antibody	DR4 Antibody: Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel death domain containing receptor was recently identified and designated DR4 (for death receptor 4). The ligand for this novel death receptor has been identified and termed TRAIL, which is a new member in the TNF family. DR4 is also called TRAIL receptor-1 (TRAIL-R1). DR4 is expressed in most of human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. Like TNFR1, Fas and DR3, DR4 mediates apoptosis and NF- κ B activation in many tissues and cells.
---	---

NCBI AND UNIPROT INFORMATION

NCBI GI #	1945072
NCBI GeneID	8797
UniProt Accession #	O00220; Q53Y72; Q96E62; A8K5I4
Molecular Weight	57 kDa
NCBI Official Full Name	cytotoxic ligand TRAIL receptor
NCBI Official Synonym Full Names	tumor necrosis factor receptor superfamily, member 10a
NCBI Official Symbol	TNFRSF10A
NCBI Official Synonym Symbols	DR4; APO2; CD261; TRAILR1; TRAILR-1
NCBI Protein Information	tumor necrosis factor receptor superfamily member 10A; TRAIL-R1; TRAIL receptor 1; death receptor 4; cytotoxic TRAIL receptor; TNF-related apoptosis-inducing ligand receptor 1; tumor necrosis factor receptor superfamily member 10a variant 2
UniProt Protein Name	Tumor necrosis factor receptor superfamily member 10A
UniProt Gene Name	TNFRSF10A
UniProt Synonym Gene Names	APO2; DR4; TRAILR1; TRAIL receptor 1; TRAIL-R1
UniProt Entry Name	TR10A_HUMAN

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://www.aaabiotech.com/polyclonal/dr4-antibody-western-blot-elisa/10950>